DCGI gives nod to phase-III clinical trial of Covovax
The vaccine has not been included in the country's inoculation programme against COVID-19
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CDSCO
Wockhardt gets CDSCO approval to export upto 100 million doses of Sputnik vaccines
Wockhardt’s bulk vaccine and fill-finish manufacturing facilities at Waluj and Shendra, Aurangabad respectively were jointly…
DCGI approves “Conditional Market Authorisation” of Covaxin and Covishield
The approval pathways through this route are fast-tracked with certain conditions to enhance the access to certain pharmaceuticals…
Covaxin demonstrates robust safety and immunogenicity in two-to-18 year old: Study
Bharat Biotech had conducted phase-II/III, open-label and multi-centre studies to evaluate the safety, reactogenicity and…
Covovax better booster for Covishield-vaccinated people: Shahid Jameel
Dr Jameel, the former head of the advisery group to the Indian SARS-COV-2 Genomics Consortia (INSACOG), said there is no data for…
DCGI seeks more data from SII over its application seeking emergency authorisation for Covovax
Serum Institute of India (SII) had sent an application to the DCGI in October for the grant of market authorisation of Covovax for…
Boehringer Ingelheim launches additional heart failure indication for Jardiance in India
Empagliflozin - the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death, in people with type-II…
Health Minister launches sixth edition of National Formulary of India (NFI)
NFI 2021 would act as a guidance document for all the healthcare professionals such as clinicians, pharmacists, nurses, dentists,…
Bharat Biotech awaits regulatory approvals to launch Covaxin for children
The SEC on COVID-19 examined the data and deliberated on the EUA application yesterday
Bharat Biotech submits clinical trial data of Covaxin in children to CDSCO
As part of the phase-II/III trial, the two-dose Covaxin was administered with 28 days apart.